CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Short Interest Update

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) was the recipient of a large growth in short interest in December. As of December 15th, there was short interest totalling 7,300,000 shares, a growth of 25.2% from the November 30th total of 5,830,000 shares. Based on an average daily trading volume, of 71,670,000 shares, the days-to-cover ratio is presently 0.1 days. Currently, 9.4% of the company’s stock are sold short.

Insiders Place Their Bets

In other news, major shareholder Bioventures Opportunities G. Yk sold 1,236,874 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $0.12, for a total transaction of $148,424.88. Following the completion of the transaction, the insider now directly owns 21,383,909 shares in the company, valued at approximately $2,566,069.08. This represents a 5.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 9,680,126 shares of company stock worth $854,423 in the last quarter. 18.00% of the stock is owned by corporate insiders.

CERo Therapeutics Stock Up 8.0 %

CERO opened at $0.06 on Tuesday. CERo Therapeutics has a 12-month low of $0.05 and a 12-month high of $12.80. The firm’s fifty day moving average price is $0.12 and its 200 day moving average price is $0.15.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.